XM does not provide services to residents of the United States of America.

Indian shares set to open higher



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares set to open higher</title></head><body>

BENGALURU, Sept 10 (Reuters) -Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and the Federal Reserve's interest rate decision.

The GIFT Nifty GIFc1 was at 25,035 points, as of 08:06 a.m. IST, indicating the NSE Nifty 50 .NSEI will open above its previous close of 24,936.4.

The benchmark Nifty 50 rose for the first time in four sessions on Monday, led by gains in consumer stocks and financials. However, all the other sectors and broader small- .NIFSMCP100 and mid-caps .NIFMDCP100 logged losses.

With most segments of the markets trading at valuations above long-term averages, focus shifts to global cues, according to analysts.

"A lot will depend on the performance of global markets, particularly the U.S., given the lack of major domestic triggers," said Ajit Mishra, senior vice president of research at Religare Broking.

Wall Street equities closed higher overnight, bouncing back from a weekly drop on Friday after mixed labour market data.

Focus now shifts to the U.S. consumer price index, due on Wednesday, which is expected to show that inflation remains on the path back to the Fed's target.

The reading will be a crucial factor influencing the size of the expected Fed rate cut next week.

Most European equities also gained on Monday on the prospect of a central bank rate cut later in the week.

Asian markets opened higher on Tuesday, though concerns over China's growth outlook kept sentiment in check. MKTS/GLOB

Both foreign portfolio investors (FPI) and domestic institutional investors (DII) were net buyers on Monday, purchasing domestic shares worth 11.77 billion rupees ($140.2 million) and 17.57 billion rupees, respectively.

Among individual stocks, drug makers Zydus Lifesciences ZYDU.NS, Alkem Laboratories ALKE.NS, Cipla CIPL.NS, Biocon BION.NS, Abbott India ABOT.NS, AstraZeneca Pharma India ASTR.NS will be in focus, after India's goods and services tax council recommended a reduction in tax rates on select cancer drugs.


STOCKS TO WATCH


** Snack-making companies like Gopal Snacks GOPA.NS, Prataap Snacks PRAT.NS, Bikaji Food BIKA.NS will be in focus after GST council recommends cutting tax rate on Namkeens to 12% from 18%.

** HG Infra Engineering HGIN.NS secures a project worth 7.81 billion rupees from Ministry of Road Transport and Highways.

** Ahluwalia Contracts AHLU.NS bags two orders worth 13.07 billion rupees from Signature Global for housing projects.


($1 = 83.9600 Indian rupees)




Reporting by Bharath Rajeswaran in Bengaluru; Editing by Rashmi Aich

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.